A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
OBJECTIVES: This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults. DATA SOURCES: Electronic databases were search...
Egile Nagusiak: | Chen, Y, Jobanputra, P, Barton, P, Jowett, S, Bryan, S, Clark, W, Fry-Smith, A, Burls, A |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
2006
|
Antzeko izenburuak
-
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
nork: Chen, Y, et al.
Argitaratua: (2006) -
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
nork: Jobanputra, P, et al.
Argitaratua: (2002) -
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
nork: Jobanputra, P, et al.
Argitaratua: (2002) -
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
nork: P. Jobanputra, et al.
Argitaratua: (2002-01-01) -
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
nork: K Malottki, et al.
Argitaratua: (2011-03-01)